It is estimated that well over 3 million people suffered from epilepsy within the united states as of 2015, now, that number may have grown or shrunk a bit since then, but that’s still around 3 million people who can potentially benefit from some sort of muscle relaxant in order to lessen the effect of their seizures and even potentially put a complete stop to them. Epilepsy can come about in a few ways which range from stroke, head injuries, tumors and the most interesting one is from external parasites within contaminated food which can lead to a central nervous system infection.
In the past, epilepsy has remained a prevalent topic when discussing the positive implications of certain chemicals derived from cannabis, more specifically CBD and THC, but what is the validity of these claims? As research begins to intensify along with a change of legislation, we may soon see these drugs being prescribed to patients all over the world very soon.
Cannabis has maintained its classification as a class B drug since it was first banned in the 70’s, which implies that it contains no therapeutic or medicinal value. Now, almost 50 years after it was banned, we are finally beginning to see the light at the end of the tunnel, through rigorous studies and research we are beginning to more thoroughly understand the value and potential implications that these chemicals may provide for people living with certain conditions that cannot or are not able to be effectively controlled through conventional methods of treatment.
The reason that CBD and THC are so valuable is that they possess the ability to pass through a thin layer of blood that conceals the brain and protects it from harmful chemicals called the blood brain barrier. They are able to do this due to their oily makeup and their similarity to other chemicals naturally produced in our body called endocannabinoids. This property allows for them to seamlessly bind with certain receptors in our brain which can lead to a state of calmness and sedation without impairing cognitive abilities. This is why as of June 2018, a drug called Epidolex was approved by the Food and Drug Administration, it is heavily based on the effects of CBD as it contains virtually no THC. This drug has been shown to effectively treat refractory epilepsy for some individuals with Dravet and Lennox Gastaut syndromes, as well as tuberous sclerosis and infantile spasms. There are also other CBD oil products that are able to be sold legally now due to the fact that they contain less than 0.2% THC.